An adenovirus-vectored recombinant vaccine confers passive immunity protection from swine acute diarrhea syndrome coronavirus challenge in neonatal mice.

An adenovirus-vectored recombinant vaccine confers passive immunity protection from swine acute diarrhea syndrome coronavirus challenge in neonatal mice.

Publication date: Dec 09, 2025

Swine Acute Diarrhea Syndrome Coronavirus (SADS-CoV), an emerging bat-origin Alphacoronavirus with demonstrated zoonotic potential, poses a significant threat to swine health and has considerable economic implications. Currently, no licensed vaccines are available. We constructed a replication-deficient human adenovirus type 5 (Ad5) vectored vaccine candidate, rAd5-SADS-S, which expresses the SADS-CoV Spike (S) glycoprotein. The rAd5-SADS-S vaccine elicited robust SADS-CoV-specific humoral immunity and potent cellular responses in both mice and pigs. Notably, rAd5-SADS-S conferred passive protection to neonatal mice against lethal SADS-CoV challenge. These findings establish a preclinical foundation for the development of SADS-CoV vaccines.

Concepts Keywords
Alphacoronavirus Adenovirus vector
Economic Spike protein
Lethal Vaccine
Mice
Vaccine

Semantics

Type Source Name
disease MESH diarrhea
disease MESH syndrome
disease MESH Ad5

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *